We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.07% | 97.27 | 97.91 | 97.07 | 97.75 | 1,045,674 | 01:00:00 |
From Nov 2023 to May 2024
By Colin Kellaher
Cytokinetics shares tumbled more than 20% on Thursday amid waning expectations that Swiss drugmaker Novartis would strike a deal to buy the heart-drug developer.
The Wall Street Journal on Monday had reported that Novartis was near a deal to buy Cytokinetics, sending shares of the South San Francisco, Calif., company soaring.
However, no deal emerged over the past couple of days, and The Journal on Thursday reported that Novartis had backed away from its pursuit of Cytokinetics, which has been running a sale process.
Cytokinetics shares were recently changing hands at $78.08, down 23%, and well below the 52-week high of $110.25 they hit Monday after The Journal's initial report.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 11, 2024 12:47 ET (17:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
